Veronique Lecault - 01 Jan 2026 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Technology Officer, Director
Signature: Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 01 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2026, 12:08:56 UTC
Previous filing: 03 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lecault Veronique	Chief Technology Officer, Director	C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA	Tryn Stimart, attorney-in-fact	05 Jan 2026	0001834418

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Award	$0	+539,265	+12%	$0.000000	5,201,069	01 Jan 2026	Common Shares	539,265	$3.42	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.